; (C) development of alternative dosage forms and strengths for the drug molecule or combinations, including the molecule; (D) other drug development activities, such as nonclinical laboratory studies and record and report maintenance; (E) pursuing new or expanded indications for such drug through supplemental applications under section 505 of the Federal Food, Drug, and Cosmetic Act